FDA seeks to drop suicide risk warnings on GLP-1 weight-loss drugs
The FDA asked manufacturers of GLP-1 weight-loss drugs (Wegovy, Zepbound, Saxenda) to remove label warnings about suicidal thoughts after reviewing 91 trials with 107,910 patients and finding no evidence of increased suicidal thoughts, behavior, or other psychiatric effects versus placebo, though earlier data could not completely rule out a small risk.